Aspirin

New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment

Retrieved on: 
onsdag, maj 8, 2024
FDA, General Health, Pharmaceutical, Health, Fetus, Cardiomyopathy, Torrent, Acidosis, Respiratory acidosis, Full, Diclofenamide, Risk, Pregnancy, Cognitive disorder, Milk, Aspirin, Metabolic acidosis, Dysgeusia, Hyperkalemia, Aplastic anemia, Partnership, PPP, Agranulocytosis, Anorexia nervosa, Human, Carbonic anhydrase inhibitor, SVP, Tablet, Incidence, Patient, Nursing, Lethargy, Serum, Hyperkalemic periodic paralysis, Diagnosis, Myopathy, Hypokalemic periodic paralysis, Paralysis, Paresthesia, Cycle, Stevens–Johnson syndrome, Hypokalemia, Quality of life, Argyreia nervosa, Sulfonamide, Coma, Pharmaceutical industry

We want to provide them with the support that they require to effectively manage their PPP.

Key Points: 
  • We want to provide them with the support that they require to effectively manage their PPP.
  • ORMALVI™ is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • Simply Stated: Research Updates in Periodic Paralysis - Quest | Muscular Dystrophy Association [online] Available at: https://mdaquest.org/simply-stated-research-updates-in-periodic-paralysis Accessed 23 Nov. 2023.
  • The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients.

Statement from March of Dimes President and CEO on CDC'S 2022 Maternal Mortality Report

Retrieved on: 
torsdag, maj 2, 2024
Education, Mortality, Risk, Pregnancy, Woman, Aspirin, CDC, Health, Death, Vaccine, Infant, White, Omicron, Mental health, Pre-eclampsia, Disease, Immunity, COVID-19, Birth control

In 2022, 817 deaths were reported, reflecting a significant decline in the maternal mortality rate compared to 2021 when over 1,200 maternal deaths were reported.

Key Points: 
  • In 2022, 817 deaths were reported, reflecting a significant decline in the maternal mortality rate compared to 2021 when over 1,200 maternal deaths were reported.
  • Despite an overall decline in the maternal mortality rate, Black women continue to experience greater risk of death during pregnancy or within 42 days of pregnancy and have a maternal mortality rate nearly three times higher than White women.
  • These racial and ethnic disparities that persist in maternal health reflect how systems and policies continue to fail people of color, especially our most vulnerable populations.
  • While the report shows that the maternal death rate has returned to pre-pandemic levels, there are still too many moms dying.

March of Dimes Launches Low Dose, Big Benefits™ Campaign to Combat Preeclampsia and Preterm Birth

Retrieved on: 
onsdag, maj 1, 2024
Education, Mortality, Element, Preterm birth, Risk, Vaccine, Philips Avent, Diagnosis, Death, FACOG, Knowledge, Pregnancy, Woman, CDC, The Harris Poll, Infant, Black, Stanford University, Faculty, Pharmacist, Media, Partner, Fear, Aspirin, Health, The Honest Company, Research, Pre-eclampsia, Mental health, MPH, Medicine, Biology, Disease, Society, Blood pressure, Quality, HCA Healthcare, IHeartRadio, Initiative, Patient, Hypertension, MBA, Birth control

ARLINGTON, Va., May 1, 2024 /PRNewswire/ -- March of Dimes, the leading organization fighting for the health of all moms and babies, today announced the launch of Low Dose, Big Benefits, a multi-year campaign aimed at decreasing the adverse effects of preeclampsia and preterm birth through the use of low dose aspirin. The new campaign will feature US Olympian and Entrepreneur Allyson Felix as a brand ambassador and is part of the March of Dimes' It Starts With Mom platform, which provides families with educational information and resources during their pregnancy journey. It Starts With Mom is generously supported by trusted partners, including HCA Healthcare, Clearblue, Goldbug, The Honest Company, Philips Avent, and Sanofi.

Key Points: 
  • Preeclampsia is a potentially fatal condition that causes a pregnant woman's blood pressure to rise and can lead to preterm birth, heart disease, and other complications.
  • Studies show that pregnant people at an increased risk for preeclampsia who take low dose aspirin may reduce their risk of preeclampsia by 15% and their risk of preterm birth by 20%.
  • Low Dose, Big Benefits is the culmination of March of Dimes' legacy since 1938 of funding research to help millions of babies survive and thrive.
  • The organization went on to create the Prematurity Campaign Roadmap in 2015 that identified eight interventions that could reduce the preterm birth rate and included low dose aspirin.

New Campaign Brings to Forefront How Preeclampsia Prevention is Possible for Pregnant Women

Retrieved on: 
onsdag, maj 1, 2024
Women, Biotechnology, Surgery, Health, Baby, Maternity, Hospitals, Consumer, Other Health, Patient, Risk, Pregnancy, Aspirin, MD, Survivor, Disease, Obesity, Exercise, Pre-eclampsia, Cardiovascular disease, FACOG, Birth control

As May marks Preeclampsia Awareness Month , leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “ Preeclampsia Prevention is Possible .” The campaign elevates awareness of a major paradigm shift underway focused on the prevention of the disease, encouraging the use of evidence-based strategies so pregnant patients and providers can actively work together to create the healthiest pregnancy possible.

Key Points: 
  • As May marks Preeclampsia Awareness Month , leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “ Preeclampsia Prevention is Possible .” The campaign elevates awareness of a major paradigm shift underway focused on the prevention of the disease, encouraging the use of evidence-based strategies so pregnant patients and providers can actively work together to create the healthiest pregnancy possible.
  • “Preeclampsia is often viewed as a complication with limited ability to intervene early and lower the risk of developing the condition,” said Eleni Tsigas, CEO of the Preeclampsia Foundation and preeclampsia survivor.
  • “However, all year long, and especially during Preeclampsia Awareness Month, we’re amplifying the message that we are in an era where we can better predict, prevent, and prevail over the adverse outcomes caused by preeclampsia.
  • “With objective, personalized data, pregnant patients can finally know their risk, create a plan and work with their care team to take every possible measure to prevent preeclampsia.”
    Patients and providers can access the educational toolkit at PreeclampsiaPrevention.com .

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
fredag, april 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

Bayer’s Consumer Health Division Announces Changes to North America Leadership Team

Retrieved on: 
tisdag, april 9, 2024
Other Communications, Other Health, Marketing, Communications, General Health, Other Natural Resources, Fitness & Nutrition, Agriculture, Natural Resources, Science, Vitamins, Supplements, Other Science, Health, Research, Medical Supplies, Growth, Philosophy, Business administration, BBDO, Diversity, University, Equity, Walmart, Bayer, Love, P&G, Aspirin, BBA, CMO, Tenneco, Multimedia, Loratadine, Advance Auto Parts, Avivi

Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.

Key Points: 
  • Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.
  • She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer.
  • View the full release here: https://www.businesswire.com/news/home/20240409885941/en/
    “I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi.
  • “I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi.

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Retrieved on: 
måndag, mars 25, 2024
Prevalence, Exercise, Gastrointestinal bleeding, Risk, GI, Sale, Nonsteroidal anti-inflammatory drug, Running, Veterinary medicine, Motion, OA, Chronic pain, Quality of life, Osteoarthritis, Arthritis, Dog, PROM, Aspirin, Cartilage, Bioelectronics, FDA, Animal, BIEL, Ibuprofen, Audit

Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment.

Key Points: 
  • The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408
    A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint.
  • BioElectronics’ Model 088 device was secured near the cervical region of the dog’s spine.
  • Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs.
  • Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
tisdag, mars 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
tisdag, mars 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
tisdag, mars 5, 2024
Senior, Tenderness, Infection, Dizziness, AbbVie, XC, Lidocaine, Swelling, Exercise, Skin, Pregnancy, History, Cyst, Red, HIV/AIDS, Trial of the century, Allergy, Social media, Incidence, Neck, Dermatology, Aspirin, Pain, Forehead, Stroke, Hyaluronic acid, Pimple, Pigment, Ibuprofen, Scar, Rash, Anaphylaxis, Chin, Learning, Weakness, Safety, Filler (linguistics), DSM-IV codes, Hypoesthesia, Clinical trial, Paratriathlon, Bleeding, Face, Jaw, ABBV, Injection, Bruise, AMI, Inflammation, FDA, TSR, U.S. FDA, Confusion, Risk, Steroid, Patient, Tell, Wound, Gram, HIV, Cheek

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.